|
Patent landscape, scope, and claims: |
US Patent 10,385,008 (RAD1901-2HCl) Claim Scope and Patent Landscape Analysis
Executive summary: US Patent 10,385,008 claims specific crystalline/solid forms of RAD1901 dihydrochloride (RAD1901-2HCl) defined by (i) X-ray powder diffraction (XRPD) peak positions at ~0% relative humidity with tight ±0.2° 2θ windows, (ii) thermal characterization (DSC onset/peak values and TGA/DSC figures), and (iii) composition and manufacturing routes using precipitation/slurrying under defined low-water conditions in specific organic solvents excluding methanol. The estate is likely “form-first”: enforceability hinges on whether an accused solid form matches the claimed XRPD peak set and whether production routes use the claimed solvent/water constraints. The strongest attack/containment risk for entrants is avoiding the XRPD-constrained polymorph set at ~0% RH and using manufacturing solvents or water contents outside the claim boundaries; the strongest protection is that multiple dependent claims create overlapping “peak-count” variants and that the XRPD claim is keyed to a defined humidity condition.
US 10,385,008: What is claimed for RAD1901-2HCl solid forms (XRPD, DSC, TGA)?
Core claim concept: The patent defines RAD1901-2HCl solid forms by analytical fingerprints rather than by bulk process parameters alone. The XRPD claims are the main literal scope anchor.
Which solid form attributes define scope at 0% relative humidity?
- Claim 1 (independent): A solid form of RAD1901-2HCl with an XRPD peak at:
- 2θ = 7.1° ± 0.2° at about relative humidity 0%.
- Claim 2: Requires additional specific peaks at 14.3° ± 0.2° alongside the 7.1° peak.
- Claims 3–10: Expand to “at least N peaks” solid forms at 0% RH, where the allowed peak lists are drawn from fixed candidate peaks, including (as reflected in your claim text):
- 7.1, 11.0, 12.0, 13.8, 14.3, 16.2, 18.3, 18.9, 25.1, 27.2 (degrees 2θ), each with ±0.2° tolerance, plus the “peak multiplicity” thresholds.
- Claim 11: A “precise set” XRPD pattern at 0% RH, requiring the combination of the listed peaks (10 peaks) together.
Practical legal impact:
- XRPD claim scope is narrow in two ways:
- it is restricted to a specific analyte (RAD1901-2HCl, not free base or mono-HCl), and
- it is anchored to peaks at specific 2θ positions with very tight tolerance and a defined humidity testing condition.
How do dependent XRPD “peak-count” claims change infringement risk?
The dependent claims (3–10) create multiple “entry points” for asserting infringement depending on what pattern an accused sample produces.
- If an accused solid form hits the 7.1° ± 0.2° peak at ~0% RH, Claim 1 is implicated.
- If it also hits 14.3° ± 0.2°, Claim 2 becomes relevant.
- If it has broader matching peaks, Claims 3–10 can be asserted based on how many peaks it meets from the approved set.
- If it matches the full set required by Claim 11, the infringement theory becomes “straightforward identity” (subject to measurement variance, sample prep differences, and RH control in testing).
What about XRPD pattern “as shown in FIG. 4G”?
- Claim 12: The solid form is defined by XRPD pattern as shown in FIG. 4G at ~0% RH.
This matters because figure-defined claims can sometimes capture what might be argued as “peak selection” disputes: instead of enumerating peaks only in text, the figure can be argued to fix an actual pattern interpretation.
What thermal properties are claimed (DSC/TGA)?
- Claim 13 (independent thermal): A RAD1901-2HCl solid form with a DSC thermogram having:
- melting onset at 218.2° C
- endothermic peak at 232.1° C
- Claim 14: DSC thermogram “as shown in the bottom figure of FIG. 8.”
- Claim 15: TGA “as shown in the top graph of FIG. 8.”
Scope implications:
- Thermal claims broaden protection beyond XRPD by adding temperature anchors and figure-defined profiles. But thermal onset/peak values often vary with heating rate, sample mass, instrument calibration, and baseline subtraction. Enforcement typically depends on proving the accused solid form yields the same thermal signature under the claimed/tested conditions.
Which pharmaceutical compositions and excipients are protected by US 10,385,008?
- Claim 16: A pharmaceutical composition comprising:
- the solid form of Claim 1, and
- one or more pharmaceutically acceptable excipients.
Scope: This is a classic “composition for the claimed solid form” claim. It provides downstream coverage for formulations using the protected polymorph/solid form, even if the formulation process does not fall within the manufacturing-route claims.
Enforcement posture: If the solid form itself is proven infringed, this claim supports additional damages and broader injunctive leverage against formulation distribution.
What process conditions for preparing RAD1901-2HCl solids are claimed (solvents, water content, precipitation/slurrying)?
What is the process claim 17’s structure?
- Claim 17: A process preparing the solid form of Claim 1, comprising:
- precipitating from a solution containing RAD1901-2HCl and a solvent, or
- slurrying RAD1901-2HCl in a solvent,
- where the solvent comprises an organic solvent excluding methanol, and
- the content of water is at or below 5% v/v.
Key constraints for manufacturing infringement:
- Methanol is excluded as part of the solvent composition.
- Water content must be ≤ 5% v/v.
- Route is limited to precipitation or slurrying from defined solutions/solvents.
What specific solvents are listed in claim 18?
- Claim 18: The process of Claim 17 where the organic solvent is selected from:
n-heptane; propyl acetate; ethyl acetate; isopropyl acetate; methyl isobutyl ketone (MIBK); methyl ethyl ketone (MEK); 1-propanol; ethanol; t-butyl methyl ether (TBME); 1,4-dioxane; toluene; 1,2-dimethoxyethane; tetrahydrofuran; dichloromethane; acetonitrile; nitromethane; and mixtures thereof.
Scope consequence:
- Claim 18 adds a second layer of specificity for solvent selection. A competitor using solvents outside this set, or using methanol as an ingredient, or using >5% v/v water, may avoid literal claim 18 (and potentially claim 17 depending on how solvent/water is interpreted).
- If an accused process uses a listed solvent but violates the water threshold, the best defense is targeting the ≤5% v/v requirement.
How strong is the patent estate for US 10,385,008 based on claim type (product-by-structure analytics vs process)?
Because the patent text you supplied is a set of claims, strength is assessed by claim breadth mechanics.
XRPD claims (1–12): strong for identity, narrower for avoidance
-
Strength drivers
- XRPD at ~0% RH is a strong definition hook. If an accused form is tested under equivalent low-RH conditions, matching peaks can prove infringement.
- Dependent “peak-count” claims (3–10) expand likelihood that some claim reads on the accused pattern.
- Claim 11’s “full set” is a tighter, higher-confidence assertion path.
-
Potential weaknesses
- XRPD sensitivity to instrumentation, sample treatment, preferred orientation, and measurement settings can create factual disputes.
- Competitors can attempt to develop a different polymorph/solvate that does not satisfy the ±0.2° 2θ set or that fails the required “peak count” thresholds at 0% RH.
Thermal claims (13–15): complementary but more variable
-
Strength drivers
- DSC onset/peak values provide quantitative anchors.
- Figure-based thermograms can help lock the fingerprint.
-
Potential weaknesses
- DSC/TGA results can shift with method parameters. If an accused solid form is close, disputes often become test-condition driven.
Process claims (17–18): strong only if manufacturing path is captured
-
Strength drivers
- A ≤5% v/v water constraint and “organic solvent excluding methanol” can be cleanly documented from batch records.
- Specific solvent enumeration in claim 18 narrows literal infringement.
-
Avoidance strategy
- Use a solvent system not in the enumerated set, include methanol, or run water above the threshold.
Composition claim (16): provides downstream leverage
If an accused product contains the protected solid form, Claim 16 can support formulation-based enforcement.
What would constitute literal infringement vs design-around for solids under US 10,385,008?
Literal infringement pathways
- XRPD-defined infringement
- The accused RAD1901-2HCl solid matches required peak(s) at ~0% RH.
- Thermal-defined infringement
- DSC onset/peak (218.2° C and 232.1° C) matches the claimed thermogram profile and conditions.
- Composition infringement
- The accused drug product formulation contains the solid form of Claim 1.
- Process infringement
- Manufacturing uses precipitation or slurrying with an organic solvent excluding methanol and water ≤5% v/v, and (for Claim 18) uses one of the listed solvents.
High-probability design-arounds
- Develop a different solid form (another polymorph or solvate) that does not present the required XRPD peaks within ±0.2° at ~0% RH.
- Ensure the manufacturing process uses methanol or water >5% v/v in the solvent system.
- Use a solvent system that is outside the enumerated list (relevant especially for Claim 18).
Patent landscape questions: what else typically surrounds a form patent like US 10,385,008?
Your prompt requests landscape analysis, but the only dataset provided here is the claim set. A complete, accurate landscape requires bibliographic and citation data (assignee, priority chain, related patents, continuations, INPADOC family members, and whether this patent is cited by or cites other RAD1901 patents). With only the claim text, a full landscape cannot be produced without risking incorrect identification of related patents.
The claims themselves indicate the patent likely sits in a common cluster:
- Earlier “API/compound” patents (covering RAD1901-2HCl itself or RAD1901 generally)
- Later “form” patents (XRPD/DSC/TGA characterized polymorphs, salts, hydrates)
- Process patents (solvent/antisolvent crystallization windows, moisture control)
But specific names, numbers, assignees, and expiry dates cannot be asserted from the provided information.
Key takeaways
- US 10,385,008 is an analytical solid-form patent for RAD1901-2HCl, with XRPD definitions at ~0% relative humidity and tight ±0.2° 2θ tolerances.
- XRPD claims 1–12 are the primary infringement hooks, with dependent claims creating multiple asserted peak-count combinations and a “full-set” claim in Claim 11.
- Thermal claims (13–15) are protective add-ons anchored by DSC onset/peak values and figure-based DSC/TGA profiles.
- Downstream protection exists via composition Claim 16 using the Claim 1 solid form plus excipients.
- Manufacturing coverage depends on process route and solvent constraints: precipitation or slurrying, organic solvents excluding methanol, and ≤5% v/v water (with additional enumerated solvent set in Claim 18).
- Design-around strategies are clear: avoid matching XRPD fingerprints at 0% RH and avoid the solvent/water constraints in the precipitation/slurry process.
FAQs
- What XRPD peak set is required to meet Claim 11 of US 10,385,008 at 0% RH?
- Does Claim 1 require both 7.1° and 14.3° peaks, or only 7.1°?
- If a solid form matches the DSC onset/peak in Claim 13 but not the XRPD peaks, can it still infringe?
- How do water content and methanol inclusion affect infringement risk under Claim 17/18?
- If a drug product uses RAD1901-2HCl but as a different solid form than Claim 1, does Claim 16 still apply?
References
No references can be cited from the information provided.
More… ↓
⤷ Start Trial
|
